Semaglutide increases the release of insulin and decreases glucose production, effectively managing blood sugar levels
In the randomized Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (intent to treat: 1,961 adults with overweight or obesity without T2D), once-weekly subcutaneous semaglutide 2.4 mg resulted in greater weight loss compared with placebo over a 68-week period (estimated treatment difference 12.4 percentage points, 95% confidence interval (CI) 13.4, 11.5
[62] Other medications with CYP1A2 inhibitory properties, including ciprofloxacin, zileuton, and certain antiarrhythmic drugs, may produce similar interactions requiring dose adjustments
Protocol for switching from high-dose tirzepatide (12.5 to 15 mg) This is the most challenging transition
Book Details INFORMATION ISBN: 9780760396162 Publisher: Quarto Publishing Group USA Inc Format: Paperback / softback Date Published: 17 July 2025 Country: United States Imprint: Fair Winds Press Illustration: 10 b-w illustrations Audience: General / adult DIMENSIONS Width: 203.0mm Height: 229.0mm Weight: 549g Pages: 224 About the Author Summer Kessel, RD, CSOWM, LDN, is a Registered Dietitian Nutrition and a Board Certified Specialist in Obesity and Weight Management with nearly twenty years of health care experience
